J
JAZZ
Jazz Pharmaceuticals Plc
246.81
-0.76-0.31%After Hours: 246.81 0.00 0.00%19:30 09/04 EDT
OPEN/PREV CLOSE238.38/240.07
TODAY RANGE236.00-241.44
VOL424.47K
MARKET CAP15.66B
52 WEEK RANGE123.88-266.38
AVG VOL (3M)885.31K
% TURNOVER0.65%
TURNOVER--
P/E (TTM)16.50
% RANGE2.27%
EPS(TTM)14.63
P/E(FORWARD)16.63
P/B3.257
BVPS74.10
DIVIDEND--
P/S3.474
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP15.16B
SHARES OUTSTANDING64.91M
NEXT EARNINGS11/03-11/09
FREE FLOAT62.82M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·8h ago
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched
Simply Wall St·1d ago
Learn Why The Bull Case For Jazz Pharmaceuticals Stock Could Change Following FDA Drug Approval
PR Newswire·09/02 20:15
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Simply Wall St·09/02 03:24
Why Jazz Pharmaceuticals (JAZZ) Is Down 6.3% After Ziihera’s First-Line HER2-Positive GEA Survival Data And What's Next
NASDAQ·09/01 16:05
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
NASDAQ·09/01 16:02
JAZZ Rises on Updated OS Results From Gastric Cancer Study
TipRanks·08/31 21:51
Jazz Pharmaceuticals Completes $1.25 Billion Notes Offering
TipRanks·08/31 12:50
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks·08/31 10:05
Jazz reports second interim overall survival results for HERIZON-GEA-01 trial
Benzinga·08/31 10:04
Jazz Reports Ziihera Outperformed Standard Treatment In Late-Stage Cancer Trial
Same Industry
Name/Symbol
Change%
Price